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We report the clinical history of a boy, affected by early-onset
epileptic encephalopathy with an episode of phenytoin neurotox-
icity, found by whole exome sequencing to carry a previously
undescribed mutation of the STXBP1 gene, combined with two
heterozygous missense mutations in the same exon of the CYP2C9
gene.* Corresponding author. Tel.: +39 089672534; fax: +39 089672578.
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Department of Medicine and Surgery, University of Salerno, Via S. Allende 1,
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reA male, was born at 40 weeks by healthy non-consanguineous
Italian parents after normal pregnancy; his body weight was
3.200 g. At 10 days, the child showed clonic movements of four
limbs in clusters, sometimes prevailing on the right side, together
with intense crying. Electroencephalography (EEG) recordings
showed interictal spike and wave (SW) discharges over the left
frontal and central areas and a widespread ictal SW discharge
associated with bilateral clonic jerks. In the following weeks, clonic
seizures manifested again several times a day with the same
features. EEG recordings showed a suppression-burst pattern
(Fig. 1A). In the ﬁrst month of life, both generalized and right sided
tonic seizures frequently recurred, poorly responsive to phenobar-
bital therapy at the daily dose of up to 6 mg/kg with a serum level
of 32 mcg/mL. Between 5 and 10 months of age, the child was
seizure-free. At 14 months, seizures manifested again during sleep,
fairly controlled by increasing the daily dose of carbamazepine upserved.
Fig. 1. STXBP1 and CYP2C9 mutations identiﬁed by exome sequencing. (A) Sleep-EEG recording at 2.5 mo, showing Ohtahara with asymmetric suppression-burst patterns
often prevailing over one hemisphere; (B) Sleep-EEG recording at 11.5 y, initial burst of a diffuse sharp wave, followed by desynchronization of the biorhythms and
generalized low-voltage spike-wave discharges. (C) Upper panel: STXBP1 gene structure; Lower panel: localization of the insertion/deletion identiﬁed by exome-sequencing
and Sanger sequencing in the patient, respect to a control (Wt) subject. (D) Sanger electropherograms showing CYP2C9 gene double heterozygosity in the patient, respect to a
control (Wt) subject; Below: functional consequences of the sequence variants, predicted with the tools indicated.
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seizures recurred with deviation of the head and eyes to the right
side, twitches of the eyelids, cyanosis of the face, followed by clonic
jerks of the right upper limb, associated with EEG rhythmic theta
activity over the left frontal-parietal regions. Seizures lasted less
than 60 s. Then, the child had alternating periods of seizure
worsening and improvement, and between 5 and 7 years, the
interictal EEGs showed SW discharges over the right or both
frontal regions. A ﬁrst brain MRI was normal, but two further MRI
studies, performed at 3 years and ﬁve months and 8 years of age
showed a mild hyperintensity of the posterior periventricular and
subcortical white matter, with a slight enlargement of lateral
ventricles, making it hypothesize a genetic etiology more than a
hypoxic-ischemic injury. Mutational scanning of SCN1A, UBE3A,
MECP2, CDKL5 genes and CGH-array and FISH analysis of the
15q11.3–13 region were negative. The child presented hypotonic
quadriplegia with postural instability, progressive scoliosis and
intentional tremor. Speech was absent. From 7 years to follow-up,
clusters of tonic-vibratory seizures, lasting no more than 10 s
recurred mainly during sleep. Video-EEG recordings showed
recurring episodes during sleep characterized by sudden eyes
opening, light ﬂexion of the head, ﬁxed staring for about 10 s
associated with a stereotypical EEG pattern (Fig. 1B). Because of
seizure persistence, phenytoin (PHT) was added to background
therapy consisting of topiramate (3 mg/kg/24 h) and clobazam
(1 mg/kg/24 h), initially at 0.5 mg/kg followed by increments of0.5 mg/kg each 5 days, up to 2.6 mg/kg/day after 2 weeks. The
child showed marked lethargy and coma and plasma PHT levels
showed unexpected values of 23.1 mg/mL. At this time, whole
metabolic work-up including serum acid-base balance, ammoni-
um, lactate, creatinine and liver function, was normal. Phenytoin
was thus discontinued and the patient quickly recovered.
Between 8 and 11 years of age, there were alternating periods
of seizure frequency increase (1–12 episodes/daily, mainly
during sleep), and clinical improvement. At age 13 years, the
child shows severe intellectual disability with aphasia and
dystonic quadriplegia.
Whole exome sequencing, performed as described by [1] (see
Supplementary material for details) revealed a new heterozy-
gous mutation in intron 6 of STXBP1 gene (RefSeq NM003165,
c.430-1delT_-2insTTGG) causing loss of the splicing acceptor
site and consequent exon 7 skipping, resulting in a truncated
protein lacking the Sec-1-like domain 2 with the introduction of
a stop codon after 19 amino acids (Fig. 1C). STXBP1 (9q34),
encoding the syntaxin binding protein 1/Munc18.1, plays a
major role in the fusion of secretory vesicles to the presynaptic
membrane, allowing release of neurotransmitters into the
synaptic cleft. Mutations of the STXBP1 gene cause disruption
in protein synthesis/degradation, leading to detrimental effects
in neurotransmitter release, have been implicated in early onset
epileptic encephalopathy with suppression bursts (EESB),
infantile spasms (IS), unclassiﬁed early-onset epileptic enceph-
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[2]. A complete classiﬁcation of the STXBP1 mutations reported
is reported in Table 1 (Supplementary material) with the main
clinical features at onset.
Interestingly, the same patient carried also a heterozygous
missense mutation in CYP2C9 (c.882G > T, p.L294F, rs544027339)
and an additional one in the same exon of this gene (c.920G > A,
p.R307K), not previously described. Functional prediction indi-
cates that both these mutations are likely to interfere with enzyme
activity (Fig. 1D). CYP2C9 is a major cytochrome enzyme involved
in the metabolic clearance of a wide variety of therapeutic agents,
including anticonvulsants such as PHT and, phenobarbital.CYP2C9
is responsible for the metabolic clearance of up to 15% of all drugs
that undergo Phase I metabolism [3]. CYP2C9 defects have been
implicated in phenytoin adverse reactions, and patients treated
with PHT could beneﬁt from CYP2C9 and CYP2C19 genotyping [4].
CYP2C9 variations found in our patient could thus correlate with
the severe adverse reaction to phenytoin titration, leading to
lethargy and coma. PHT has a narrow therapeutic window (10–
20 mg/mL) and adverse drug reactions become common with
levels >10 mL/mL, with remarkable, dose-dependent neurological
side effects. A further rise in drug levels may lead to cerebellar
atrophy, lethargy, coma, and even precipitate status epilepticus.
To the best of our knowledge, there are no previous report on
the co-occurrence of mutations in the STXBP1 gene and variants of
the CYP2C9 gene. This may be in part explained by the fact that
most of the reported cases with STXBP1 mutations have been
identiﬁed by sequencing focused on this single gene, instead of the
whole exome sequencing approach applied here, that allowed
identiﬁcation of a new STXBP1 mutation in this severe epilepticencephalopathy coexisting with a compound heterozygosity in the
CYP2C9 gene that helps explain the serious PHT neurotoxicity that
occurred in this child.
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Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.seizure.2015.
11.004.
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